As of August 2026, VRTX's current EPS stands at $17.33, according to the latest financial reports. For the year 2025, the company recorded an earnings per share (EPS) of $15.46, which marks an increase compared to its EPS of -$2.08 in 2024. VRTX reported an EPS of $4.34 for the quarterly report ending on Jun 30, 2026.
For 2025, Vertex Pharmaceuticals's EPS was $15.46, an increase of 843.3% from -$2.08 in 2024. For the fiscal quarter that ended on Jun 30, 2026, the per-share earnings was $4.34, showing a 8% increase from the same quarter last year. For the twelve months ending June 2026, the EPS is $17.33. For the year 2024, the yearly earnings per share was -$2.08, marking a decrease of 114.8% from 2023.
During the last 12 months, Vertex Pharmaceuticals has seen an EPS growth of 8% (YoY, quarterly). Examining a broader timeline, the company maintained an average EPS growth rate of 6% per year for the last three years. During the last 5 years, the company had an average EPS growth rate of 8.2%.
| Stock name | Price to Earnings | EPS grwoth 1Y | EPS grwoth 3Y | EPS grwoth 5Y |
|---|---|---|---|---|
| BMY Bristol-Myers Squibb Company | 14.73 | 178.7% | 5.3% | N/A |
| JNJ Johnson & Johnson | 30.96 | 90.6% | 17.7% | 14.8% |
| VRTX Vertex Pharmaceuticals Inc | 31.62 | 843.3% | 6% | 8.2% |
| ABBV Abbvie Inc | 74.64 | -1.3% | -29.1% | -2.8% |
| MRK Merck & Co Inc | 120.12 | 8% | 8.4% | 21.2% |
| GILD Gilead Sciences Inc | N/A | 1,700% | 23.2% | 132.8% |
| ENTA Enanta Pharmaceuticals Inc | N/A | 29.9% | N/A | N/A |
All data is based on quarterly TTM periods, unless otherwise specified.